resp30tb + isoniazid + rifampicin + pyrazinamide + ethambutol

This drug is a fixed-dose combination product containing **resp30tb**, **isoniazid**, **rifampicin**, **pyrazinamide**, and **ethambutol**. It is used as a first-line therapy for active tuberculosis, specifically following standardized WHO treatment guidelines. These agents act synergistically to reduce the risk of drug resistance and improve treatment adherence. Isoniazid inhibits mycolic acid synthesis in the mycobacterial cell wall; rifampicin inhibits RNA polymerase; pyrazinamide disrupts membrane energetics and transport in acidic environments; ethambutol targets arabinosyl transferase, inhibiting cell wall synthesis. The combination is typically used during the intensive phase of TB therapy, administered orally, and intended to maximize efficacy and prevent bacterial resistance[1][3][4][6]. Combination therapy improves compliance and reduces prescription errors and selective drug intake.

Other names

resp30tbresp-30tbresp 30tb